**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 67358

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Serum gastrin-17 concentration for prediction of upper gastrointestinal tract bleeding risk among peptic ulcer patients**

Wang JX *et al*. Serum G-17 and bleeding ulcer risk

Jun-Xian Wang, Yu-Ping Cao, Peng Su, Wei He, Xiao-Ping Li, Ya-Meng Zhu

**Jun-Xian Wang, Yu-Ping Cao, Peng Su, Wei He, Xiao-Ping Li, Ya-Meng Zhu,** Department of Gastroenterology, The Second People’s Hospital of Anhui Province, Hefei 230011, Anhui Province, China

**Author contributions:** Wang JX and Su P contributed study concept, design, analysis and interpretation of data; Cao YP, Su P, He W, Li XP and Zhu YM contributed acquisition of data; Wang JX, Cao YP and Su P wrote the manuscript; all authors wrote, read and approved the final manuscript.

**Corresponding author: Jun-Xian Wang, PhD, Chief Doctor,** Department of Gastroenterology, The Second People’s Hospital of Anhui Province, No. 1868 Dangshan Road, Hefei 230011, Anhui Province, China. ahwjx168@sina.com

**Received:** April 25, 2021

**Revised:** June 18, 2021

**Accepted:** August 30, 2021

**Published online:**

**Abstract**

BACKGROUND

Serum gastrin-17 (G-17), pepsinogen I (PGI), and pepsinogen II (PGII) concentrations regulate gastric acid secretion, and hypersecretion of gastric acid increases the risks of peptic ulcer and upper gastrointestinal bleeding. These associations suggest that serum G-17, PGI, and (or) PGII may predict gastrointestinal bleeding risk among peptic ulcer patients.

AIM

To evaluate the efficacies of serum G-17, PGI, PGII, and PGI/PGII ratio (PGR) for predicting upper gastrointestinal bleeding among peptic ulcer patients.

METHODS

A total of 199 patients diagnosed with peptic ulcer confirmed by gastroscopy and positivity for *Helicobacter pylori* by the 14C-urea breath test were recruited, including 107 patients with simple peptic ulcer and 92 cases complicated by upper gastrointestinal bleeding. Serum PGI, PGII, G-17, and PGR were measured by immune methods and compared between bleeding and non-bleeding groups by univariate analysis. The specificity and sensitivity of PGs and G-17 for evaluating upper gastrointestinal bleeding risk were then assessed by constructing receiver operating characteristic (ROC) curves.

RESULTS

Serum G-17 was significantly higher among peptic ulcer patients with upper gastrointestinal bleeding compared to simple peptic ulcer patients (25.34 ± 14.29 *vs* 8.84 ± 8.03 pmol/L, *t* = 9.822, *P* < 0.01), whereas serum PGI, PGII, and PGR did not differ significantly between bleeding and non-bleeding groups (all *P* > 0.05). The risk of bleeding was significantly higher among peptic ulcer patients with elevated serum G-17 (> 15 pmol/L) compared to patients with normal or low serum G-17 (73.2% *vs* 27.4%, *χ*2 = 40.72, *P* < 0.01). The area under the ROC curve for serum G-17 was 0.866 ± 0.024, and a cut-off of 9.86 pmol/L yielded 90.2% sensitivity and 68.2% specificity for distinguishing peptic ulcer with and without upper gastrointestinal bleeding.

CONCLUSION

Serum G-17 is significantly upregulated in peptic ulcer patients and higher levels are predictive of upper gastrointestinal bleeding. Conversely, serum PGI, PGII, and PGR have no predictive value. Further prospective studies are warranted to examine if high G-17 can be used to assess risk of bleeding prior to onset.

**Key Words:** Peptic ulcer; Upper gastrointestinal bleeding; Gastrin; Pepsinogen; Receiver operating characteristic curve

Wang JX, Cao YP, Su P, He W, Li XP, Zhu YM. Serum gastrin-17 concentration for prediction of upper gastrointestinal tract bleeding risk among peptic ulcer patients. *World J Clin Cases* 2021; In press

**Core Tip:** Upper gastrointestinal tract bleeding is a severe complication of peptic ulcer that markedly increases mortality. Bleeding risk is elevated by hypersecretion of gastric acid, and secretion rate is associated with serum concentrations of gastrin 17 (G-17), pepsinogen I, and pepsinogen II. Thus, these values may predict bleeding risk among peptic ulcer patients. Indeed, bleeding risk was elevated in patients with G-17 above the normal range (> 15 pmol/L), and serum G-17 > 9.86 pmol/L distinguished bleeding from non-bleeding patients with 90.2% sensitivity and 68.2% specificity. Elevated G-17 may be an effective early predictor of bleeding from peptic ulcer.

**INTRODUCTION**

Peptic ulcer is among the most common digestive system diseases, and upper gastrointestinal bleeding is the most prevalent complication. Hypersecretion of gastric acid is a critical risk factor for peptic ulcer bleeding, and secretion level is strongly correlated with serum concentration of the gut-derived peptide hormone gastrin-17 (G-17)[1,2]. High serum levels of pepsinogen I (PGI) and PGII are also associated with gastric acid secretion rate by the gastric mucosa and with the incidence of peptic ulcer[3]. Conversely, low serum PGI and PGI/PGII ratio are associated with gastric atrophy. Thus, modulation of G-17, PGI, and PGII secretion levels can be utilized to treat dyspepsia and other gastric diseases[4]. High serum gastrin or PGI/PGII ratio (PGR) will lead to excessive secretion of gastric acid, overcoming the protective capacity of the gastric mucosa and increasing the incidence of peptic ulcer and digestive tract tumors[5]. Indeed, combined detection of serum G-17 and PG is a fundamental screening method for early gastric cancer detection[6]. However, serum PGI, PGII, and G-17 levels among peptic ulcer patients with and without bleeding have not been examined in detail. In the present study, these levels were measured and their predictive values for assessing the risk of peptic ulcer complicated by upper gastrointestinal bleeding tested by univariate and receiver operating characteristic (ROC) curve analyses.

**MATERIALS AND METHODS**

***Baseline data***

Patients diagnosed with peptic ulcer or peptic ulcer complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Anhui No.2 Provincial People’s Hospital from July 2015 to November 2019, were recruited. Serum levels of G-17, PGI, and PGII were measured and the PGR was calculated. Candidates were excluded due to the following conditions: (1) Malignant tumors or severe atypical hyperplasia as indicated by endoscopic pathology; (2) Negative for *Helicobacter pylori* (HP) or not tested for HP; (3) History of stomach, esophagus or duodenum surgery; (4) Serious cardiopulmonary diseases that may independently influence gastrin or PG secretion; (5) Long-term use of aspirin or clopidogrel, or recent administration of antiplatelet/anticoagulant drugs such as heparin; (6) History of long-term non-steroidal anti-inflammatory analgesic or glucocorticoid administration; (7) Peptic ulcer complicated by other severe digestive system diseases; (8) Stress ulcer or stress ulcer complicated by bleeding; (9) Non-ulcerative upper gastrointestinal bleeding due to other causes; (10) Long-term history of proton pump inhibitor administration; and (11) Diagnosis of gastrinoma. A total of 199 patients were enrolled meeting the inclusion and exclusion criteria, including 138 males and 61 females with a mean age of 50.43 ± 16.16 years. Among these patients, 107 had peptic ulcer without bleeding [75 males and 32 females, mean age 52.6 ± 14.7 years], including 49 cases of duodenal ulcer, 45 of gastric ulcer, and 13 cases of complex ulcer. The other 92 patients were diagnosed with peptic ulcer complicated by upper gastrointestinal bleeding [63 males and 29 females, mean age 47.9 ± 17.4 years], including 64 cases of duodenal ulcer, 20 cases of gastric ulcer, and 8 cases of complex ulcer. Patients with gastric ulcer or complex ulcer received routine pathological examination to exclude the possibility of high-grade neoplasia or malignancy, whereas those with duodenal ulcer with or without bleeding did not undergo routine pathological examination. All patients were confirmed to be HP–positive by the 14C-urea breath test. Patients with peptic ulcer complicated by bleeding were significantly younger than patients with peptic ulcer alone (47.9 ± 17.4 *vs* 52.61 ± 14.74, *P* = 0.040), whereas the sex ratio did not significantly differ between the groups (Table 1).

***Blood sample collection, processing, and hormone detection***

Approximately 5 mL of fasting (for about 6 h) blood was collected, and the serum was separated for subsequent immunofluorescence measurements of PGI, PGII, and G-17. A serum pepsinogen and G-17 kit was purchased from BIOHIT Healthcare (Hefei) and a microplate reader from Anthos Labtec Instruments (Austria).

***Reference ranges of PGI, PGII, PGR and G-17***

The reference ranges of these concentrations are as follows: PGI, 70–165 μg/L; PGII, 3–15 μg/L; PGR, 7%-20%; G-17, 1-15 pmol/L. Serum PGI > 165 μg/L, serum PGII >15 μg/L, PGR > 20, and G17 > 15 pmol/L were regarded as elevated.

***Statistical analysis***

All statistical analyses were conducted using SPSS16.0 (SPSS Inc., Chicago, IL, United States). The serum levels of PGI, PGII, G-17, and PGR were compared between bleeding and non-bleeding groups by independent samples *t*-test. The proportions of peptic ulcer cases complicated by bleeding were compared between patient subgroups stratified according to upper-range cut-offs (*e.g*., greater or less than 15 pmol/L for G-17) by the *Chi*-square test. The efficacy of G-17 for predicting bleeding complication was assessed by ROC curve analysis. A *P* < 0.05 (two-tailed) was considered statistically significant for all tests.

**RESULTS**

***Elevated serum G-17 in peptic ulcer patients with bleeding***

Serum G-17 concentration was significantly higher in peptic ulcer patients with upper gastrointestinal bleeding compared to non-bleeding patients (*t* = 9.822, *P* < 0.01) (Table 2). Furthermore, serum G-17 was also significantly higher in gastric ulcer (GU) patients with bleeding and duodenal ulcer (DU) patients with bleeding compared to corresponding non-bleeding subgroups (both *P* < 0.01). Serum G-17 was slightly higher in DU patients without bleeding compared to GU patients without bleeding (*P* = 0.209), but did not differ between GU patients with bleeding and DU patients with bleeding (*P* = 0.940). Serum G-17 was also higher among patients with complex ulcer (CU) complicated by bleeding compared to patients with CU alone, but again the difference did not reach significance (*P* > 0.05). In contrast to G-17, there were no significant differences in serum PGI, PGII, and PGR between the bleeding and non-bleeding subgroups (all *P* > 0.05, Table 2). Thus, serum G-17 (but not PGI, PGII, or PGR) may be useful for distinguishing bleeding from non-bleeding peptic ulcer patients.

***Association between serum G-17 level and bleeding risk***

Serum G-17 ranging from 1 to 15 pmol/L is considered normal. Therefore, we first compared bleeding incidence between peptic ulcer patients stratified by a serum G-17 cut-off of 15 pmol/L. Among peptic ulcer patients with serum G-17 > 15 pmol/L, approximately 73.2% exhibited bleeding compared to only 27.4% of patients with serum G-17 < 15 pmol/L (*χ*2 = 40.72, *P*<0.01) (Table 3). In contrast, the proportions of bleeding cases did not differ between groups stratified by similar upper limits in serum PGI, PGII, and PGR (*χ*2 = 0.395, *χ*2 = 0.009, and *χ*2 = 2.242, respectively, all *P* > 0.05).

***Efficacies of serum G-17, PGI, PGII, and PGR for predicting bleeding complication among peptic ulcer patients***

The area under the ROC curve (AUC) of serum G-17 for peptic ulcer patients with or without upper gastrointestinal bleeding was 0.866 ± 0.024. According to the Youden index, the optimal serum G-17 cut-off value for distinguishing bleeding from non-bleeding patients was 9.86 pmol/L, yielding 90.2% sensitivity and 68.2% specificity (Figure 1). In contrast, the AUC values for serum PGI, PGII, and PGR were only 0.599, 0.496, and 0.598, respectively, indicating low efficacy for distinguishing bleeding from non-bleeding peptic ulcer (Figure 2).

**DISCUSSION**

We report that serum gastrin concentration is significantly elevated above normal reference ranges in patients with gastric or duodenal ulcer, and is even higher among patients with peptic ulcer complicated by upper gastrointestinal bleeding. Indeed, the proportion of peptic ulcer patients with serum G-17 concentrations above the upper limit of normal (approximately 15 pmol/L) was significantly greater among those with bleeding compared to patients without bleeding (simple GU). Furthermore, ROC curve analysis revealed that G-17 > 9.86 pmol/L distinguished bleeding from non-bleeding GU patients with high sensitivity and moderate specificity, suggesting that G-17 evaluation prior to endoscopic examination could be employed to assess bleeding risk, thereby facilitating timely intervention, such as a higher proton pump inhibitor dose[7], and improving overall prognosis. Serum G-17 was also higher among complex ulcer (CU) patients with bleeding compared to CU patients without bleeding, although the difference did not reach statistical significance due to the small sample size. Hence, larger-scale studies are warranted to fully assess the efficacy of high G-17 for prediction of bleeding among GU patient subgroups, including prospective studies directly evaluating the association between baseline G-17 and future bleeding.

Approximately 10% of individuals will develop gastric or duodenal ulcer over a lifetime, but the majority can be completely cured with treatment. However, GU complicated by acute upper gastrointestinal bleeding increases treatment difficulty and can be life-threatening if uncontrolled[8]. Therefore, identifying predictive indices for upper gastrointestinal bleeding is critical for improving prognosis among more severely afflicted GU patients.

The incidence and severity of peptic ulcer are significantly associated with the production rates of gastric acid, gastrin, and pepsin[9]. Gastrin is a pre-hormone secreted by G-cells in the gastric antrum that is then converted to active molecules, mainly G-34 and G-17, of which G-17 accounts for approximately 80%–90% of the total bioactivity. The main physiological functions of gastrin are to stimulate gastric acid and PG secretion, regulate gastrointestinal motility, increase gastric mucosal blood flow, and promote gastric mucosal growth and nutrition[10]. However, excessive gastric acid secretion by high serum G-17 may destroy the gastric mucosa, leading to ulcer formation and possibly bleeding. In the presence of gastric acid, PG is rapidly converted into active pepsin, which can cause the dissolution of blood clots and thus impair the control of bleeding. Consequently, it is rational to speculate that high G-17 and high PG may predict the risk of bleeding among peptic ulcer patients. However, serum PG was unrelated to bleeding incidence, possibly because many factors can influence PG production aside from gastric acid secretion rate. In fact, the secretion of gastric acid, gastrin, and PG can be affected by multiple factors. For instance, HPinfection increases gastrin secretion[11]. Hence, all patients enrolled in the present study were HP-positive to eliminate the effects of HP and related factors. In addition, long-term use of proton pump inhibitors may cause a compensatory increase in gastrin secretion[12], so patients receiving proton pump inhibitors were also excluded from the present study. Furthermore, peptic ulcer patients with other conditions associated with bleeding risk were eliminated, so the difference between groups likely reflects disease severity, further underscoring the importance of serum G-17 for evaluation of patient condition and prognosis. On the other hand, as yet unidentified factors influencing PG may have obscured differences between bleeding and non-bleeding patients.

Such PG measurements may still have clinical value. Pepsinogen can be classified as PGI or PGII according to immunogenicity, and these isoforms are generated by different regions of the gastric mucosa. Therefore, separate detection of serum PGI and PGII can provide an estimate of region-specific gastric acid secretion rate[13]. Activated pepsin can both enhance the risk of peptic ulcer and impair coagulation, potentially enhancing bleeding risk and diminishing treatment efficacy. In this study, however, serum PGI, PGII, and PGR were not associated with bleeding, possibly because PG secretion is affected to a greater extent by gastric mucosal atrophy, dysplasia, and other diseases than by ulcer (with or without bleeding)[14].

Although we controlled for multiple factors potentially influencing the secretion rates of G-17 and PG, factors such as drinking[15], smoking[16], age[17], and gastric mucosal lesions[18] may have differed between the groups. Thus, larger-scale studies allowing for more extensive subgroup analyses are required to validate the current finding that serum G-17 is a major predictive factor for bleeding among peptic ulcer patients.

**CONCLUSION**

In summary, serum G-17 is significantly elevated in peptic ulcer complicated by bleeding. Serum G-17 > 9.86 pmol/L distinguishes bleeding from non-bleeding cases with high sensitivity, suggesting its clinical utility for predicting bleeding risk.

**ARTICLE HIGHLIGHTS**

***Research background***

Peptic ulcer is a relatively common chronic gastrointestinal disorder most frequently caused by *Helicobacter pylori* infection or long-term non-steroid anti-inflammatory drug administration. Severe cases are often complicated by bleeding, which can exacerbate symptoms, cause anemia, and lead to life-threatening hemorrhage. Hypersecretion of gastric acid increases the risk and severity of peptic ulcer. Gastric acid secretion is controlled by the hormones gastrin-17 (G-17), pepsinogen I (PGI), and pepsinogen II (PGII), suggesting that these factors may be predictive of bleeding among peptic ulcer patients.

***Research motivation***

If left untreated, peptic ulcer can result in gastrointestinal bleeding and gastric tumors. Therefore, accessible biomarkers such as serum factors predictive of bleeding risk are important tools for early diagnosis and treatment guidance, and may reduce the incidence of severe complications.

***Research objectives***

To examine if serum G-17, PGI, PGII, and (or) PGI/PGII ratio (PGR) can predict bleeding risk among peptic ulcer patients.

***Research methods***

We compared serum G-17, PGI, PGII, and PGR between 199 peptic ulcer patients with bleeding (*n* = 92) or without bleeding (*n* = 107), and then assessed the efficacy of each factor for bleeding prediction by receiver operating characteristic curve analysis.

***Research results***

Serum G-17 was significantly higher among peptic ulcer patients with upper gastrointestinal bleeding, whereas serum PGI, PGII, and PGR did not differ significantly between bleeding and non-bleeding patients. A serum G-17 greater than 9.86 pmol/L distinguished bleeding from non-bleeding patients with 90.2% sensitivity and 68.2% specificity.

***Research conclusions***

Elevated serum G-17 is predictive of bleeding risk among peptic ulcer patients. Lowering serum G-17 should be a major goal of clinical intervention.

***Research perspectives***

Prospective studies are warranted to assess if elevated serum G-17 can predict bleeding complication prior to disease onset. The development of drugs able to regulate G-17 secretion is also desired to help reduce bleeding risk.

**REFERENCES**

1 **Schubert ML**. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. *Curr Opin Gastroenterol* 2017; **33**: 430-438 [PMID: 28787289 DOI: 10.1097/MOG.0000000000000392]

2 **Schubert ML**, Rehfeld JF. Gastric Peptides-Gastrin and Somatostatin. *Compr Physiol* 2019; **10**: 197-228 [PMID: 31853955 DOI: 10.1002/cphy.c180035]

3 **Zhou B,** Chen X, Huang B, Hu YH , Tang GR Zhang J, Lin Q. Changes in serum pepsinogen levels and their value as a predictor of treatment outcomes in children with pepticulcer. *J Paediatr Child Health* 2019; **55**: 1103-1106 [PMID: 30659684 DOI: 10.1111/jpc.14365]

4 **Iijima K**, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, Shimosegawa T. Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. *World J Gastroenterol* 2009; **15**: 853-859 [PMID: 19230047 DOI: 10.3748/wjg.15.853]

5 **Burkitt MD**, Varro A, Pritchard DM. Importance of gastrin in the pathogenesis and treatment of gastric tumors. *World J Gastroenterol* 2009; **15**: 1-16 [PMID: 19115463 DOI: 10.3748/wjg.15.1]

6 **Yuan L**, Zhao JB, Zhou YL, Qi YB, Guo QY, Zhang HH, Khan MN, Lan L, Jia CH, Zhang YR, Ding SZ. Type I and type II *Helicobacter pylori* infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area. *World J Gastroenterol* 2020; **26**: 3673-3685 [PMID: 32742135 DOI: 10.3748/wjg.v26.i25.3673]

7 **Tringali A**, Manta R, Sica M, Bassotti G, Marmo R, Mutignani M. Comparing intravenous and oral proton pump inhibitor therapy for bleeding peptic ulcers following endoscopic management: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2017; **83**: 1619-1635 [PMID: 28181291 DOI: 10.1111/bcp.13258]

8 **Rotondano G**. Epidemiology and diagnosis of acute nonvariceal upper gastrointestinal bleeding. *Gastroenterol Clin North Am* 2014; **43**: 643-663 [PMID: 25440917 DOI: 10.1016/j.gtc.2014.08.001]

9 **Park SM**, Park HS. G- and D-cell populations, serum and tissue concentrations of gastrin and somatostatin in patients with peptic ulcer diseases. *Korean J Intern Med* 1993; **8**: 1-7 [PMID: 7903552 DOI: 10.3904/kjim.1993.8.1.1]

10 **Germaná B**, Di Mario F, Cavallaro LG, Moussa AM, Lecis P, Liatoupolou S, Comparato G, Carloni C, Bertiato G, Battiestel M, Papa N, Aragona G, Cavestro GM, Iori V, Merli R, Bertolini S, Caruana P, Franzé A. Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care. *Dig Liver Dis* 2005; **37**: 501-508 [PMID: 15975537 DOI: 10.1016/j.dld.2005.01.016]

11 **Liu W**, Sun Y, Yuan Y. Analysis of serum gastrin-17 and Helicobacter pylori antibody in healthy Chinese population. *J Clin Lab Anal* 2020; **34**: e23518 [PMID: 32864830 DOI: 10.1002/jcla.23518]

12 **Waldum HL**, Hauso Ø, Fossmark R. The regulation of gastric acid secretion - clinical perspectives. *Acta Physiol (Oxf)* 2014; **210**: 239-256 [PMID: 24279703 DOI: 10.1111/apha.12208]

13 **Miraglia C**, Moccia F, Russo M, Scida S, Franceschi M, Crafa P, Franzoni L, Nouvenne A, Meschi T, Leandro G, De' Angelis GL, Di Mario F. Non-invasive method for the assessment of gastric acid secretion. *Acta Biomed* 2018; **89**: 53-57 [PMID: 30561418 DOI: 10.23750/abm.v89i8-S.7986]

14 **Kwak MS**, Kim N, Lee HS, Lee HE, Jung HC, Song IS. Predictive power of serum pepsinogen tests for the development of gastric cancer in comparison to the histologic risk index. *Dig Dis Sci* 2010; **55**: 2275-2282 [PMID: 20306133 DOI: 10.1007/s10620-010-1181-x]

15 **Singer MV**, Leffmann C, Eysselein VE, Calden H, Goebell H. Action of ethanol and some alcoholic beverages on gastric acid secretion and release of gastrin in humans. *Gastroenterology* 1987; **93**: 1247-1254 [PMID: 3678743 DOI: 10.1016/0016-5085(87)90252-6]

16 **Fletcher DR**, Shulkes A, Hardy KJ. The effect of cigarette smoking on gastric acid secretion and gastric mucosal blood flow in man. *Aust N Z J Med* 1985; **15**: 417-420 [PMID: 3866537 DOI: 10.1111/j.1445-5994.1985.tb02763.x]

17 **Pilotto A**, Vianello F, Di Mario F, Plebani M, Farinati F, Azzini CF. Effect of age on gastric acid, pepsin, pepsinogen group A and gastrin secretion in peptic ulcer patients. *Gerontology* 1994; **40**: 253-259 [PMID: 7959081 DOI: 10.1159/000213593]

18 **Parhusip DH**, Siregar GA, Dairi LB. The Difference of Serum Gastrin-17 Level Based on Gastritis Severity and Helicobacter Pylori Infection. *Open Access Maced J Med Sci* 2019; **7**: 1266-1269 [PMID: 31110567 DOI: 10.3889/oamjms.2019.325]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Second People's Hospital of Anhui Province, Institutional Review Board (Approval No. 2015-036).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors have no potential competing interests to declare.

**Data sharing statement:**  No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** April 25, 2021

**First decision:** June 3, 2021

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Farid K **S-Editor:** Wang LL **L-Editor:** Webster JR **P-Editor:**

**Figure Legends**

![C:\Users\马玉杰\AppData\Roaming\Tencent\Users\623573717\QQ\WinTemp\RichOle\M]){2LH%0~JVE](I)IJTH5O.png]()

**Figure 1 Efficacy of serum gastrin-17 for distinguishing peptic ulcer with or without upper gastrointestinal bleeding.**

![C:\Users\马玉杰\AppData\Roaming\Tencent\Users\623573717\QQ\WinTemp\RichOle\OX6Q]6{}ZN9F}QR~1]RUQ75.png]()

**Figure 2 Efficacies of serum pepsinogen I, pepsinogen II and pepsinogen ratio for distinguishing peptic ulcer with or without upper gastrointestinal bleeding.** PGI: Pepsinogen I; PGII: Pepsinogen II; PGR: PGI/PGII ratio.

**Table 1 Demographic distributions of peptic ulcer patients with and without bleeding**

|  |  |  |
| --- | --- | --- |
| **Group** | **Sex**  | **Age1 (yr)** |
| **Male**  | **Female**  |
| Peptic ulcer without bleeding | 75 | 32 | 52.6 ± 14.7 |
| Peptic ulcer complicated by bleeding | 63 | 29 | 47.9 ± 17.4a |
| Total | 138 | 61 | 50.43 ± 16.16 |

1mean ± SD.

a*P* < 0.05 compared to the non-bleeding group.

**Table 2 Serum pepsinogen I, pepsinogen II, pepsinogen ratio, and gastrin-17 values for patient subgroups stratified by bleeding complication and ulcer type**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **Number of cases (*n*)** | **PGI (μg/L)** | **PGII (μg/L)** | **PGR (PGI/II)** | **G-17 (pmol/L)** |
| Peptic ulcer group | GU | 45 | 197.90 ± 89.97 | 20.40 ± 13.70 | 11.46 ± 4.70 | 7.24 ± 8.43 |
| DU | 49 | 224.43 ± 80.60 | 23.19 ± 17.05 | 12.58 ± 5.33 | 9.17 ± 6.33 |
| CU | 13 | 220.48 ± 107.82 | 24.09 ± 10.16 | 10.70 ± 5.86 | 13.11 ± 10.91 |
| Total | 107 | 225.86 ± 91.10 | 21.68 ± 14.47 | 12.74 ± 5.51 | 13.03 ± 13.20 |
| Peptic ulcer complicated with upper gastrointestinal bleeding group | GU | 20 | 240.52 ± 83.47 | 22.10 ± 15.30 | 15.15 ± 13.20 | 26.13 ± 13.68a |
| DU | 64 | 250.64 ± 85.70 | 19.22 ± 10.71 | 14.91 ± 5.32 | 25.84 ± 15.00 a |
| CU | 8 | 238.55 ± 95.15 | 18.30 ± 7.51 | 14.70 ± 6.31 | 19.32 ± 8.87 |
| Total  | 92 | 234.98 ± 90.67 | 19.65 ± 12.25 | 14.44 ± 7.39 | 25.34 ± 14.29a |

a*P* < 0.01 compared to the corresponding non-bleeding group. PGI: Pepsinogen I; PGII: Pepsinogen II; PGR: PGI/PGII ratio; G-17: Gastrin-17; GU: Gastric ulcer; DU: Duodenal ulcer; CU: Complex ulcer.

**Table 3 Association between serum gastrin-17 and upper gastrointestinal bleeding**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Serum G-17 level** | **Peptic ulcer, *n* (%)** | **Peptic ulcer complicated by bleeding, *n* (%)** | **Total, *n*** | ***P* value** |
| Normal (≤ 15 pmol/L) | 85 (72.6) | 32 (27.4) | 117 |  |
| Elevated (> 15 pmol/L) | 22 (26.8) | 60 (73.2) | 82 |  |
| Total | 107 | 92 | 199 | 0.000 |

G-17: Gastrin-17.